These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19717225)

  • 1. Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
    Antonarakis ES; Carducci MA; Eisenberger MA
    Cancer Lett; 2010 May; 291(1):1-13. PubMed ID: 19717225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.
    Pommery N; Hénichart JP
    Mini Rev Med Chem; 2005 Dec; 5(12):1125-32. PubMed ID: 16375758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
    PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future directions in castrate-resistant prostate cancer therapy.
    Antonarakis ES; Carducci MA
    Clin Genitourin Cancer; 2010 Dec; 8(1):37-46. PubMed ID: 21208854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
    Heidegger I; Massoner P; Eder IE; Pircher A; Pichler R; Aigner F; Bektic J; Horninger W; Klocker H
    J Steroid Biochem Mol Biol; 2013 Nov; 138():248-56. PubMed ID: 23792785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses.
    Härmä V; Virtanen J; Mäkelä R; Happonen A; Mpindi JP; Knuuttila M; Kohonen P; Lötjönen J; Kallioniemi O; Nees M
    PLoS One; 2010 May; 5(5):e10431. PubMed ID: 20454659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
    Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
    Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.
    Morgan TM; Koreckij TD; Corey E
    Curr Cancer Drug Targets; 2009 Mar; 9(2):237-49. PubMed ID: 19275762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
    Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
    Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on mTOR inhibitors for castration-refractory prostate cancer.
    Burgio SL; Fabbri F; Seymour IJ; Zoli W; Amadori D; De Giorgi U
    Curr Cancer Drug Targets; 2012 Oct; 12(8):940-9. PubMed ID: 22831278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.
    Collak FK; Yagiz K; Luthringer DJ; Erkaya B; Cinar B
    J Biol Chem; 2012 Jul; 287(28):23698-709. PubMed ID: 22619175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.
    Pang X; Yi Z; Zhang J; Lu B; Sung B; Qu W; Aggarwal BB; Liu M
    Cancer Res; 2010 Mar; 70(5):1951-9. PubMed ID: 20160026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.